Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05424224 · ClinicalTrials.gov registry record
Using rTMS to Treat Depression
A clinical trial of Depression, sponsored by Florida International University.
- Active
- Registry status
- 30
- Enrollment target
- 1
- Study location
NCT05424224: Active study of Depression, sponsored by Florida International University.
NCT05424224 is a study of Depression that is active but no longer recruiting, run by Florida International University. The registered enrollment target is 30 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05424224, a study of Depression, is active but no longer recruiting, sponsored by Florida International University.
- ACTIVE NOT RECRUITING
- Registry status
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Repetitive Transcranial Magnetic Stimulation (rTMS) is a promising, novel, non-invasive therapy for depression. In fact, there is an FDA-approved depression protocol to stimulate the dorsolateral prefrontal cortex (dlPFC). Its efficacy and safety have improved significantly with continued research and clinical experience. However, it is not known how to identify potential patients who would benefit most from treatment. The primary goal of this study is to determine if changes in specific electroencephalogram (EEG) parameters after treatment can predict whether patients are responders or non-responders to rTMS. The second objective is to analyze changes in the functional connectivity of specific brain regions in responders compared to non-responders. The hypothesis is that through rTMS treatment, investigators will be able to increase the activity in the frontal region that includes the dorsolateral prefrontal cortex (DLPFC). Scalp EEG signals will be processed in order to compare EEG brain connectivity and Frontal alpha asymmetry index (FAA) to determine if there are differences before and after the treatment. EEG FAA is usually calculated by subtracting the right-side EEG power estimates from the respective counterpart on the other side. According to literature, depressive patients seem to have comparatively higher left frontal alpha power. Cortical activity is related to a reduced EEG power, which is reflected in depressed subjects. On the other hand, higher alpha power could also be interpreted as inhibition. Investigators will try to delineate changes in resting EEG functional connectivity before and after high-frequency left prefrontal rTMS, by using biomarkers such as: time/frequency connectivity, Alpha asymmetry index, among others. TMS also allows cortical properties, such as excitability, inhibition, oscillatory activity and connectivity to be directly probed within a specific region of the cortex. Other studies suggest that alterations in gamma oscillat
Primary Outcome
Resting-state Electroencephalogram (EEG) can serve as an assessment signal that will determine the benefits of the treatment and the efficacy of this procedure. Frequency domain features will be extracted to analyze the change over the time of the treatment. Connectivity maps will be derived for the most important frequency bands( Delta, Theta, Alpha, and Beta).
Conditions Studied
Interventions
- DEVICE MagVita
Study Locations (1)
Florida
- Florida International University - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-01-09 |
| Est. Completion | 2026-09-25 |
What the registry record for NCT05424224 still lists
NCT05424224 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 786-participant average among 679 other Depression trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Depression appearing as the primary indexed condition, and to 1 intervention - of which MagVita is the first listed.
NCT05424224 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT05424224 about?
NCT05424224 is a clinical study titled "Using rTMS to Treat Depression". Repetitive Transcranial Magnetic Stimulation (rTMS) is a promising, novel, non-invasive therapy for depression. In fact, there is an FDA-approved depression protocol to stimulate the dorsolateral prefrontal cortex (dlPFC). Its efficacy and safety have improved significantly with continued research a...
What is the current status of trial NCT05424224?
This trial is currently active not recruiting. The enrollment target is 30 participants. The study started on 2023-01-09. Estimated completion is 2026-09-25.
What conditions does trial NCT05424224 study?
This clinical trial studies the following conditions: Depression.
What interventions are being tested in trial NCT05424224?
The interventions under investigation include: MagVita (DEVICE).
Who is sponsoring clinical trial NCT05424224?
This trial is sponsored by Florida International University, which has 89 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05424224 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05424224's enrollment target sits among peer trials
30 557th of 679 higher than 105 of 679 other Depression trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Reaching Out to Distressed Medical Residents, Fellows and Faculty
RECRUITING · NA
-
Depression and Driving
RECRUITING
-
Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder
RECRUITING · Phase 1
-
Sleep to Reduce Incident Depression Effectively in Peripartum
RECRUITING · Phase 2
-
PET Imaging of Cyclooxygenase in Participants With Major Depressive Disorder (MDD)
RECRUITING · Phase 1
-
Identifying and Treating Depression in the Orthopaedic Trauma Population
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy